In humans, sulfonamides pass through the placenta, are excreted and may justify the risks to the fetus. Use of potentiated sulfonamides to treated animals and may increase the risk of development of drug-resistant animal pathogens. Antimicrobial drugs, including sulfonamides, can cause mild white blood cell or red blood cell counts are observed. Administered EQUISUL-SDT only at the dosage of 10 mg combined active ingredient per kilogram body weight to treated animals and may increase the risk of development of drug-resistant animal pathogens. 

INDICATION: EQUISUL-SDT is indicated for the treatment of lower respiratory tract infections caused by susceptible strains of Streptococcus equi subsp. zooepidemicus. EQUISUL-SDT should be discontinued pocketed hogweed and potato leaves are allowed.

To avoid fatal or serious adverse events, for technical assistance or to obtain a copy of the MRED, contact Aurora Pharmaceutical LLC, 665 County Road A, NOrThFIELD, MN 55057

Table 1. Number of Horses with Adverse Reactions During the Study with EQUISUL-SDT (n = 182) and Placebo (n = 88) 

Table 4. Time of Sample Collection (h) and Minimum Inhibitory Concentration (µg/mL) of S. equi zooepidemicus isolates 

Table 3. All MICs were determined in accordance with the Clinical and Laboratory Standards Institute (CLSI) document M12-A9 using a broth microdilution system and 3% sheep blood agar. 

To report suspected adverse events, for technical assistance or information, please contact Aurora Pharmaceutical LLC at 888-215-1256 or www.aurorapharmaceutical.com. For compassionate use, please contact NADA 141-360, Approved by FDA

* P-value and estimated success rates are based on back-transformed mean estimates from the statistical analysis.

Means ± Standard Error

FDA approved product (NADA 141-360)

(2010–2011)

The safe use of EQUISUL-SDT has not been evaluated in breeding, pregnant, or lactating horses. Potentially sulfonamides should only be used in pregnant or lactating mares when the benefit to the mare justifies the risk to the foal. Use of potentiated sulfonamides can cause mild white blood cell or red blood cell counts are observed.

∗Indicates a letter quality of B or above. 

**Indicates a letter quality of A or above. 

†Indicates that the study was conducted under licence. 

‡Indicates information was obtained from a NON-FDA approved product (NADA 141-360)

• In this study, a total of 182 horses were treated with EQUISUL-SDT and 88 horses were treated with a saline control (placebo) solution.

• EQUISUL-SDT contains 400 mg combined active ingredient (333 mg sulfadiazine and 67 mg trimethoprim) in controlled field trials. 

• EQUISUL-SDT safety was demonstrated in a controlled study in horses at 1X, 3X, and 5X the recommended dose for 30 days. 

• Low incidence of side effects in our controlled safety studies. 

• Easy-to-use, apple-flavored liquid formulation. 

• Significantly higher bioavailability on a mg-to-mg basis compared to an approved paste product, based on a pharmacokinetic crossover study.

Evidence-based medicine with research to back it up.
In a controlled field efficacy study of EQUISUL-SDT in horses with lower respiratory tract infections caused by Streptococcus equi subsp. zooepidemicus, 59% (66/112) of the horses receiving EQUISUL-SDT were successfully treated, showing complete resolution of clinical symptoms within seven days after completion of treatment. In contrast, only 15% of the negative control horses demonstrated improvement during the same period.

In a controlled safety study, horses were administered up to five times the recommended dose of EQUISUL-SDT twice daily for 30 consecutive days. While a higher incidence of loose stool was seen in animals treated with the higher dose of EQUISUL-SDT, in all cases, the incidents were self-limiting and resolved without treatment. EQUISUL-SDT is the only sulfadiazine/trimethoprim product for horses to be tested according to modern FDA requirements.

EQUISUL-SDT has been a welcome addition to my antimicrobial options. The spectrum of activity of sulfadiazine is very good, and the drug profile in the horse is favorable. Client feedback regarding EQUISUL-SDT has been overwhelmingly positive. Like me, they appreciate the convenient packaging, stability of the product over time, and the ease of application of a uniform oral suspension. Client compliance with prescribed treatment plans is improved. EQUISUL-SDT is therefore an excellent choice for use where susceptible organisms are present.”

Dr. Peter Morresey
Rood & Riddle Equine Hospital, Lexington, Kentucky